Short Interest in Hims & Hers Health, Inc. (NYSE:HIMS) Declines By 19.7%

Hims & Hers Health, Inc. (NYSE:HIMS) saw a significant drop in short interest during the month of June. As of June 15th, there was short interest totalling 17,000,000 shares, a drop of 19.7% from the May 31st total of 21,160,000 shares. Based on an average daily trading volume, of 9,370,000 shares, the short-interest ratio is presently 1.8 days. Approximately 11.3% of the shares of the company are sold short.

Hims & Hers Health Stock Up 0.8 %

NYSE HIMS traded up $0.17 during trading on Friday, hitting $20.19. 20,714,279 shares of the stock traded hands, compared to its average volume of 11,021,090. Hims & Hers Health has a 12-month low of $5.65 and a 12-month high of $25.74. The firm has a 50-day simple moving average of $17.59 and a 200-day simple moving average of $13.55. The company has a market capitalization of $4.34 billion, a P/E ratio of -2,019.00 and a beta of 1.08.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The firm had revenue of $278.20 million during the quarter, compared to analyst estimates of $270.37 million. During the same period last year, the firm posted ($0.05) earnings per share. Hims & Hers Health’s revenue for the quarter was up 45.8% compared to the same quarter last year. As a group, research analysts predict that Hims & Hers Health will post 0.2 EPS for the current fiscal year.

Insider Activity at Hims & Hers Health

In related news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $14.97, for a total transaction of $2,827,653.36. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $14.97, for a total transaction of $2,827,653.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Soleil Boughton sold 2,503 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $15.65, for a total transaction of $39,171.95. Following the completion of the transaction, the insider now owns 166,866 shares in the company, valued at $2,611,452.90. The disclosure for this sale can be found here. Insiders have sold 962,791 shares of company stock valued at $16,930,725 over the last ninety days. Insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Several hedge funds have recently made changes to their positions in the business. Forerunner Ventures Management LLC bought a new stake in Hims & Hers Health in the fourth quarter worth $86,836,000. Farallon Capital Management LLC raised its stake in shares of Hims & Hers Health by 3,890.5% in the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after acquiring an additional 1,634,000 shares during the period. M&G Plc bought a new stake in shares of Hims & Hers Health in the 1st quarter worth about $8,232,000. Vanguard Group Inc. boosted its stake in shares of Hims & Hers Health by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock worth $88,857,000 after purchasing an additional 428,671 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in Hims & Hers Health by 39.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,272,750 shares of the company’s stock worth $8,006,000 after purchasing an additional 357,590 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on HIMS shares. Jefferies Financial Group raised their price objective on Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday. Citigroup downgraded shares of Hims & Hers Health from a “buy” rating to a “neutral” rating and lifted their price target for the company from $16.00 to $20.00 in a report on Wednesday, May 22nd. TheStreet upgraded shares of Hims & Hers Health from a “d” rating to a “c” rating in a research report on Monday, March 4th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Hims & Hers Health from $14.00 to $16.00 and gave the company a “hold” rating in a research report on Tuesday, May 7th. Finally, Bank of America upped their target price on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Thursday, June 13th. Seven investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.00.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.